Abstract

SANTOS MORIN, L; LOMBARDERO PIN, M; MATEOS EGIDO, E  and  VELAZ SUAREZ, MA. Adverse psychiatric effects with lorlatinib, a medicine that has not been widely used. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.1, pp.78-79.  Epub Jan 18, 2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000100021.

Non-small cell lung cancer (NSCLC) is the most common cause of death worldwide. Selective molecular treatments have been an important advance in the treatment of NSCLC in certain patients whose tumors have diverse mutations such as EGFR, BRAF, ALK rearrangement or ROS.

Lorlatinib is an ALK-selective TKI that it is able to penetrate the brain and it has highly activity against ALK and ROS1 fusions, including resistance mutations. We describe the case of a woman with non-small cell lung cancer who has an adverse psychiatric effect in relation to lorlatinib.

Keywords : Lorlatinib; ROS1-rearrangement; psychiatric effect.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )